Correction to: Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease
Lal C, Strange C. Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. Expert Opin. Pharmacother. 2015;16(3):427–34
Following publication of this article, errors have been identified in the “Declaration of interest” section. The word ‘monies’ is repeated twice and one of the occurrences should be removed. The correct disclosure section is given below:
Declaration of interest
C Strange is a consultant and received travel monies from AstraZeneca, Baxter, CSL Behring and Grifols in the past year on subjects related to COPD. He has received grants from Actelion, Alpha-1 Association, Alpha-1 Foundation, CSL Behring, Entera Health, NIH and Pearl Therapeutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.